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Because chemokine receptor 5 (CCR5) may have a 
role in pulmonary immune response, we explored whether 
patients with severe pandemic (H1N1) 2009 were more 
likely to carry the CCR5Δ32 allele than were members 
of the general population. We found a large proportion of 
heterozygosity for the CCR5Δ32 allele among white pa-
tients with severe disease.
C
hemokine receptor 5 (CCR5) is a protein that belongs 
to the β-chemokine receptor family and is expressed 
primarily on T cells, macrophages, and dendritic cells. 
CCR5 plays a role in mediating leukocyte chemotaxis in 
response to its ligands, which include RANTES, MIP-1a, 
and MIP-1b. It may help direct many immune cell subsets, 
including regulatory T cells and Th17 cells, to sites of in-
fection. CCR5 is also 1 of 2 common co-receptors for HIV. 
Until recently, understanding the role of CCR5 in support-
ing the antiviral immune response was limited to apprecia-
tion of the role of receptor deﬁ  ciency in protecting from 
HIV infection and disease progression. Persons who are 
homozygous for the CCR5Δ32 allele, a condition in which 
a 32-bp deletion in the CCR5 gene prevents its expression 
on the cell surface, have been shown to have reduced sus-
ceptibility to HIV infection; the heterozygous state delays 
HIV disease progression (1–3).  However, homozygosity 
of the Δ32 allele has recently been shown to be associated 
with increased risk for symptomatic and fatal West Nile vi-
rus infection (4). This association was conﬁ  rmed in a larger 
meta-analysis (5); CCR5 facilitated directed movement of 
lymphocytes during infection in a mouse model of West 
Nile virus infection (6). A case report of an adverse reaction 
to the yellow fever virus vaccine in a person heterozygous 
for CCR5Δ32 and a link between the CCR5Δ32 allele and 
severe tickborne encephalitis symptoms suggest that CCR5 
may play a role in the immune response to other ﬂ  avivirus 
infections as well (7,8). Several reports have suggested a 
potential effect of the CCR5Δ32 allele on the response to 
inﬂ  uenza viruses. In mouse models, CCR5 is pivotal in di-
recting CD8+ T cells to lung airways during challenge with 
Sendai virus (9); similarly, deaths among CCR5–/– mice in-
crease after infection with inﬂ  uenza A virus (10). Because 
of the range of severity of recent pandemic (H1N1) 2009 
infections and the possible role for CCR5 in the pulmonary 
immune response, we sought to determine whether patients 
requiring intensive care admission and respiratory support 
for severe pandemic (H1N1) 2009 were more likely to car-
ry the CCR5Δ32 allele than were members of the general 
population.
The Study
In response to the outbreak of pandemic (H1N1) 2009 
in Mexico, we conducted an observational study of critical-
ly ill patients with this infection in Winnipeg, Canada. The 
research was approved by the local research ethics board. 
The study protocol is described in detail (11). 
We examined blood samples from 20 patients with 
laboratory-conﬁ  rmed pandemic (H1N1) 2009. Average pa-
tient age was 40.35 years.  Ethnicity was nonwhite for 10 
patients, white for 9, and unknown for 1. 
Peripheral blood mononuclear cells were stored, and a 
subset of samples were thawed and resuspended in 200 uL 
phosphate-buffered saline. Genomic DNA was extracted 
by using the QIAamp DNA Mini Kit (QIAGEN, Valencia, 
CA, USA) according to the manufacturer’s instructions. 
DNA was ampliﬁ  ed by using previously reported primers 
surrounding the 32-bp deletion in the CCR5 gene: 5′ prim-
er, TCATTACACCTGCAGCTCTC; 3′ primer, TGGT-
GAAGATAAGCCTCAC. Wild-type CCR5 DNA results 
in a 197-bp product, but the Δ32 allele results in a 165-bp 
product. The genotype was determined by visual examina-
tion of the PCR product and of a known heterozygote used 
as a control. 
The CCR5Δ32 allele was not found in the nonwhite 
patients, but it was found in 5 of the 9 white patients 
(Figure); overall allele frequency for white patients was 
27.8%. Among the 5 who were heterozygous for the 
CCR5Δ32 allele, 1 died, 1 remained in the intensive care 
unit for >1 month, and 3 were discharged.
Conclusions
The outbreak of pandemic (H1N1) 2009 infection in 
Canada affected primarily young women; a preponderance 
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tions. Risk factors identiﬁ  ed included a history of lung 
disease or smoking, obesity, hypertension, and diabetes.   
The frequency of CCR5Δ32 heterozygosity among white 
populations has been reported to range from 10% to 15% 
(12,13); we found CCR5Δ32 heterozygosity at a higher 
than expected frequency (55.5%) among white patients with 
critical illness caused by pandemic (H1N1) 2009. Although 
deﬁ  ciency of the receptor protects against acquisition of 
HIV, evidence is accumulating to suggest it plays a role in 
severity of illness caused by ﬂ  avivirus infections (7,8). In 
animal models of inﬂ  uenza, CCR5 plays a role in direct-
ing CD8+ T cells to the site of infection, and its absence is 
associated with increased mortality rates (9,10); however, 
to our knowledge  a similar association in humans has not 
yet been reported. Our observation suggests that CCR5Δ32 
is 1 of the factors associated with increased severity of ill-
ness among white patients with pandemic (H1N1) 2009. 
Identifying genetic factors associated with greater risk for 
illness severity will help explain the unique pathogenesis 
displayed in the pandemic (H1N1) 2009 outbreak and may 
have public health implications. Further studies are required 
to illuminate the role of CCR5 in delivery of immune cells 
to the site of inﬂ  uenza infection.
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Figure. Ampliﬁ  cation of the chemokine 
receptor 5 (CCR5) Δ32 locus in white 
patients. Lane 1, heterozygous 
positive control; lanes 2–5 and 
7–11, patient samples; lane 6, 100-
bp ladder; lane 12, negative control. 
CCR5Δ32 heterozygosity is observed 
in samples 2, 3, 4, 5, and 11.
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